Unlike existing treatment options, eXIthera's inhibitors offer the potential to prevent thrombosis without the bleeding liabilities commonly associated with these treatments. Their lead IV candidate, Frunexian, has completed Phase 1 trials and has demonstrated safety, tolerability, and an ideal clinical PK profile, along with a validated efficacy marker. One of the breakthroughs achieved by eXIthera is the establishment that effective anticoagulation can be achieved using their small molecule therapeutic without the risk of increased bleeding or the need for a reversal agent.

This has the potential to save lives and significantly reduce healthcare costs by preventing major bleeding events. eXIthera's innovative approach to addressing bleeding complications associated with antithrombotic agents has gained recognition, with the U. S.

Food and Drug Administration (FDA) accepting their Investigational New Drug (IND) application for a Phase 2 clinical trial. Headquartered in Westborough, MA, eXIthera Pharmaceuticals is at the forefront of developing safer and more effective treatments for thrombosis prevention through their cutting-edge science and pipeline of small molecule inhibitors. Contact eXIthera today to learn more about their groundbreaking advancements in the field of coagulation